share_log

Arcutis Biotherapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Watanabe Todd Franklin

SEC announcement ·  Mar 2 05:17
Summary by Futu AI
Todd Franklin Watanabe, associated with Arcutis Biotherapeutics, completed a sale of 2,465 shares of common stock on February 28, 2024. The transaction was executed at a price of $10.60 per share, resulting in a total market value of $26,129. Following the sale, Watanabe directly holds 889,436 shares of the company. Additionally, Watanabe has indirect ownership of 231,140 shares through trusts and an LLC. The sale took place in an open market or private sale, as per the transaction code description.
Todd Franklin Watanabe, associated with Arcutis Biotherapeutics, completed a sale of 2,465 shares of common stock on February 28, 2024. The transaction was executed at a price of $10.60 per share, resulting in a total market value of $26,129. Following the sale, Watanabe directly holds 889,436 shares of the company. Additionally, Watanabe has indirect ownership of 231,140 shares through trusts and an LLC. The sale took place in an open market or private sale, as per the transaction code description.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.